P&G Q2 FY2026-27 Results: Sales Remain Flat At ₹1,145 Crore, But Profit Falls 7% To ₹196 Crore; Shares Decline After Earnings Declared

Procter & Gamble (P&G) Hygiene and Health Care Limited reported sales of ₹1,145.08 crore for the quarter ended 30 September 2026, broadly unchanged compared with ₹1,150.17 crore from the year-ago period. Profit after tax (PAT) declined 7% to ₹196 crore.

The company said profitability faced a double-digit impact from commodity-cost fluctuations, raw material and energy costs, and unfavourable foreign exchange rates. Its productivity programme offset a significant part of the pressure. P&G also continued investing in innovation and advertising to support its long-term competitiveness.

On 12 November 2026, the P&G share price closed at ₹7,190.50, down 0.17% on the National Stock Exchange (NSE). The stock opened at ₹7,268, against the previous close of ₹7,202.50. P&G shares touched an intraday high of ₹7,274 and a low of ₹6,922.

P&G Q2 FY27 Results: Increased Expenses

The company's total income edged up to ₹1,162.09 crore from ₹1,160.07 crore, supported by other income of ₹17.01 crore.

Total expenses increased to ₹900.07 crore from ₹878.29 crore. The cost of raw and packing materials rose to ₹237.87 crore from ₹197.49 crore, while purchases of traded goods increased to ₹237.52 crore from ₹211.64 crore. Employee benefit expenses also climbed to ₹54.86 crore from ₹48.59 crore.

Profit before tax (PBT) declined to ₹262.02 crore from ₹281.78 crore. Total tax expense was ₹66.18 crore, against ₹71.92 crore a year earlier. Earnings per share (EPS) also fell to ₹60.33 from ₹64.65.

P&G H1 FY27 Shows Lower Profit

For the first half of FY27, revenue from operations was ₹2,036.54 crore, lower than ₹2,037.20 crore a year earlier. PAT declined to ₹322.11 crore from ₹401.92 crore.

Total expenses rose to ₹1,631.33 crore from ₹1,558.31 crore. Advertising and sales promotion expenses stood at ₹249.94 crore, compared with ₹244.70 crore in the year-ago period. The company reported cash and cash equivalents of ₹715.80 crore as of 30 September 2026, against ₹557.02 crore at the end of March 2026.

The company also cited products launched in the first half of the year, such as upgraded Vicks ZzzQuil with Ashwagandha and Vicks medicated lozenges. It continued to focus on Whisper Period Pants and consumer engagement initiatives.

Sources

NSE Archive

Official Press Release

NSE

Also Read - Closing Bell, 12 November 2026: Range-Bound Session Sees Sensex And Nifty Close In The Green At The End Of Today’s Trade